Head-to-head evidence
Suzetrigine vs VX-993
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Diabetic Peripheral Neuropathic Pain
Shared mechanism: Voltage-gated sodium channel NaV1.8 · full Diabetic Peripheral Neuropathic Pain pipeline
Suzetrigine
Marketed by Vertex Pharmaceuticals
NCT05660538 · Phase 2 · completed
The trial randomized 194 participants to three suzetrigine doses or active-controlled pregabalin, using quadruple blinding and matched placebos; the primary endpoint was the clinical symptom measure of change in weekly average pain score. The reported within-group pain changes were similar across arms, but statistical significance for the between-group primary comparisons is not provided, so the result is unclear rather than definitively met.
Next expected readout: January 2027 · NCT06696443 (registry estimate)
VX-993
Developed by Vertex Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT06619860 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Suzetrigine's landscape · VX-993's landscape